dose of 2 ϫ 10 6 CD34-positive cells/kg below which hematologic recovery was significantly delayed and transfusion requirements increased, however follow-up was too short Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood proto determine progression-free survival. In the present study, we assessed engraftment, response rate, and long-term progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 × 10 6 CD34 cells/kg (range 1.2-gression-free and overall survival in 55 patients with advanced multiple myeloma receiving CD34-selected blood 30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage cell autotransplants. colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils Ͼ0.5 × 10 9 /l and platelets Ͼ20 × 10 9
Diagnosis and staging of multiple myeloma used pubpositive stem cells lished criteria. 21 Patients were entered if they had one or more of the following features: (1) serum IgG Ͼ5 g/dl, IgA Ͼ3 g/dl, or urine M component Ͼ4 g/24 h; (2) osteolytic High-dose chemotherapy with marrow transplantation has bone lesions or radiographic evidence of diffuse osteoproduced high response rates and prolonged progressionporosis; and (3) ␤ 2 -microglobulin Ͼ3 mg/l. Patients with free survival for patients with multiple myeloma. [1] [2] [3] [4] [5] [6] nonsecretory myeloma were eligible if there was evidence Although allogeneic transplantation may offer potential of extensive bone marrow plasmacytosis. Patients were benefit for some patients, most cannot receive this therapy excluded for major cardiac, pulmonary, gastrointestinal, because of advanced age at presentation, co-morbid disease, neurologic or hepatic disease; serum creatinine Ͼ2 mg/dl; and a high risk of treatment-related mortality. [7] [8] [9] Thus, variage greater than 70 years; or Karnofsky performance status ous forms of autologous hematopoietic stem cell support Ͻ70%. Patients were also excluded from study for disease are commonly used to treat myeloma patients. [10] [11] [12] [13] [14] [15] One refractory to conventional chemotherapy or initially responproblem with this approach is probable contamination of sive and subsequently progressive on chemotherapy. 18 the graft with myeloma cells, thus contributing to early Patients receiving Ͼ1 year of alkylator-based chemorelapse.
therapy, were also ineligible. We and others previously reported that selection of cells in the graft expressing CD34 may provide a source of hemCytapheresis and cryopreservation atopoietic support with a minimum of residual tumor cell contamination. [16] [17] [18] [19] [20] These studies suggested a threshold Blood progenitor cells were collected after cyclophosphamide 2.5 g intravenously, prednisone 2 mg/kg orally daily for 4 days, and granulocyte colony-stimulating factor (G- Patients surviving greater than 1 month were evaluable for response by skeletal radiography, urine and serum electrosaline (PBS) to remove unbound antibody. 23 The antibodytreated cells were passed successively through a 15 × 2. 5 phoresis, bone marrow biopsy and serum creatinine, albumin, and ␤ 2 -microglobulin. These were done pretransplant, cm Chromaflex column containing 20 ml avidin-biogel until a minimum of 1.0 ϫ 10 6 CD34-positive cells/kg were monthly for 4 months and then every 2 months thereafter until disease progression or relapse. Complete remission obtained (CellPro, Bothell, WA, USA). Cells were cryopreserved in 10% dimethyl sulfoxide by control-rate freezing was defined as normal bone marrow cellularity, less than 5% plasma cells, no paraprotein in serum and urine by and stored in the gas phase of liquid nitrogen. A back-up bone marrow harvest sample was cryopreserved in all immunoelectrophoresis or immunofixation, and no evidence of progressive bone lesions. Partial remission was patients.
defined as a у75% reduction from diagnosis of bone marrow plasmacytosis and serum or urine paraprotein levels, CD34 enumeration without progression of bone lesions. Minimal response was defined as a reduction in serum or urine paraprotein by Cell counts were performed using a Coulter counter Ͻ75%. Disease progression was defined as the day when (Coulter Electronics, Hialeah, FL, USA). 0.5 to 1 ϫ 10 6 bone marrow recurrence and/or new lytic bone disease on cells were obtained from the leukapheresis product, the radiograph and progressive M-component (Ͼ25% increase) flow-through fraction from the CEPRATE column were detected. (CellPro, Bothell, WA, USA), and from the adsorbed fracComparisons of patient features were performed using tion. Cells were incubated on ice in the dark for 30 min the Wilcoxon rank sum test. 25 Comparison of the frequency with 20 l of anti-CD34 monoclonal antibody (MoAb; of freedom from progression and survival between groups HPCA2) conjugated with phycoerythrin (Becton Dickinson, was used with the Fisher's exact test. 25 Comparison of Palo Alto, CA, USA) or the appropriate isotype control means was calculated by 2 test. Patients were analyzed (murine IgG1 conjugated with phycoerythrin) (Becton for survival and progression-free survival from the time of Dickinson). Samples were run on a FACScan flow cytotransplantation using the product-limit method of Kaplan meter (Becton Dickinson) and 50 000 events were acquired.
and Meier. 26 Summary estimates include actuarial survival Data were analyzed using Lysis II software (Becton fractions at 95% confidence intervals. Multivariate analysis Dickinson) as previously described. 18 was done with Cox regression. Analyses were performed using the BMDP statistical package.
25 P values were two-sided.
Conditioning regimen
Busulfan (0.875 mg/kg orally four times daily on days Ϫ7 to Ϫ4) and cyclophosphamide (60 mg/kg intravenously Results over 1 h daily on days Ϫ3 and Ϫ2) were given to all patients. 18, 22 Patients with neutrophils Ͻ0.5 ϫ 10 9 /l were in Subjects single rooms and received nystatin and norfloxacin or cipFifty-five patients with chemotherapy-responsive or stable rofloxacin. Patients with temperatures Ͼ38.5°C received multiple myeloma entered the study. Clinical characteristics imipenem or cefoperazone-sulbactam or other broad-specare shown in remission is 20 months and the actuarial survival 3 years from transplant is 47 Ϯ 17% (Figure 2 ). alkylating agents with or without VAD (24 patients), and other treatments (15 patients). platelets Ͼ20 ϫ 10 9 /l, two with hepatic veno-occlusive distreatment, the risk of recurrent myeloma persists up to 5 years after transplant. In a study of 470 myeloma patients, ease, two with early infection, and one with slow hematologic recovery. Median numbers of units of RBC and plate-73% of whom underwent two cycles of dose-intensive chemotherapy and autologous peripheral blood progenitor lets transfused were 7 and 3, respectively. Eight patients received fewer than 2 ϫ 10 6 CD34-positive cells/kg and cell transplantation, Vesole and colleagues 31 demonstrated actuarial 3-year progression-free and overall survival of had a statistically significant increased requirement for RBC and platelet transfusion and a prolonged time to plate-35% and 67%, respectively, results similar to that which has been described in this study and others for patients let recovery (P = 0.013, 0.003 and Ͻ0.001, respectively). 18 There was grade III/IV hepatic dysfunction in nine undergoing a single cycle of myeloablative conditioning. [15] [16] [17] patients. Nine patients developed pulmonary toxicity requiring corticosteroid therapy. Grade III or IV stomatitis There may be several reasons for myeloma recurrence. First, the myeloablative preparative regimen is insufficient was common and there were six treatment-related deaths from pneumonia (three patients), hepatic veno-occlusive to eradicate the malignant plasma cell clone. A variety of different preparative regimens are associated with 5-10% disease (two patients) and gastrointestinal bleeding (one patient). Other toxicities consisted of hemorrhagic cystitis treatment-related mortality, similar response rates and progression-free and overall survival in the range of 12-26 and (seven patients), reversible renal dysfunction (15 patients), and supraventricular dysrhythmia (three patients).
Hematologic recovery and toxicity
36-60+ months, respectively. 11, 15, 17, 31, 32 Second, progressive disease may be the result of multiple myeloma contaminating the autologous bone marrow or blood stem cell graft. Allogeneic bone marrow transplantation, although limited Discussion to a younger population with HLA-matched sibling donors, offers the only form of hematopoietic support which is Based on the high response rates achieved with aggressive combinations of alkylating agents, dose-intensive chemocompletely free of tumor contamination. [7] [8] [9] The largest study of allogeneic bone marrow transplantation demontherapy and autologous bone marrow transplantation has been studied in multiple myeloma. 3, 6, 10, 11, 27 One early strated a median progression-free and overall survival of 10 and 18 months, respectively, a 3-year actuarial proapproach that we and others studied was to change the source of hematopoietic support from bone marrow to autogression-free survival of Ͻ30%, and a relapse rate of 50%, suggesting that even a product free of tumor contamination logous peripheral blood progenitor cells obtained by leukapheresis. 13, 17, 22 The leukapheresis product may contain may not prevent recurrence. Furthermore, high treatmentrelated mortality in the first year led the authors to conclude fewer clonogenic myeloma cells, and thus provide an improved source of hematopoietic support. Other possible that allogeneic bone marrow transplant offered no advantage in disease control when compared to autologous bone ways to reduce the risk of myeloma contamination in the source of hematopoietic support is through purification of marrow transplant. From these results it appears that relapse following dosethe leukapheresis material either with a battery of anti-B cell antibodies, 16, 27, 28 or by positive selection for hematointensive preparative conditioning and autologous or allogeneic transplantation may be a result of residual chemopoietic progenitor cells. 18, 19 Because myeloma cells lack uniform expression of B cell therapy-resistant disease. 33,34 A phase III trial comparing CD34-selected autologous progenitor cell transplantation antigens, positive hematopoietic progenitor cell selection is a more feasible approach of progenitor cell purification. 18, 29 with unselected progenitor cell transplantation met its accrual target in January 1997; further follow-up on that Furthermore, the CD34-selection process produced a product capable of rapid hematopoietic recovery after myetrial will be required to determine the impact of selection on progression-free survival. loablative preparative conditioning with busulfan and cyclophosphamide. Now, after a longer follow-up, we assessed the impact of CD34-selected autotransplants on progression-free survival in patients with intermediate-to
